Servier names David K. Lee Executive VP of the United States

As Executive Vice President, David will lead Servier's activities in the US and help to form its market strategy in this key region

Independent pharmaceutical group Servier has appointed David K. Lee as its Executive Vice President for the United States.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like

Manufacturing

Servier inaugurates €150m API production unit at Normandy site

The new production unit will be responsible for the manufacture of an active ingredient used to treat venous diseases
Manufacturing

Servier to develop and commercialise targeted solid tumour therapy, BDTX-4933

Through a worldwide licensing agreement, Servier will commercialise Black Diamond Therapeutics' targeted small molecule therapeutic for patinets with RAF/RAS-mutant solid tumours
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Pall Corporation wins supply contract with Servier

The filtration specialist will supply exclusive tech and services to Servier's new biomanufacturing site in France
Manufacturing

Bringing preparative chromatography into the spotlight

Effective and selective preparative chromatography purification can provide higher quality products and decrease time to market
Manufacturing

Servier appoints MaSTherCell to develop its cell therapy manufacturing platform

MaSTherCell is developing CAR-T cell therapy manufacturing platform, enabling industrial manufacturing of Servier products
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Subscribe now